Table 4.
TTFields-Related Local Adverse Events
| Source | Diagnosis | Patients, No. | Mild-Moderate dAEs | Severe dAEs | Headache | Heat Sensation | Electric Sensation |
|---|---|---|---|---|---|---|---|
| Kirson et al. 2007 | rGBM | 10 | 90% | ||||
| Kirson et al. 2009 | ndGBM | 10 | 100% | 20% | |||
| Stupp et al. 2012 (EF-11) | rGBM | 120 | 16% | ||||
| Mrugala et al. 2014 (PRiDe) | rGBM | 457 | 24.30% | 5.70% | 11.30% | 7.70% | |
| Stupp et al. 2017 (EF-14) | ndGBM | 456 | 52% | 2% | |||
| Onken et al. 2019 | ndGBM + rGBM | 30 | 40% | 3% | |||
| Korshoej et al. 2019 | rGBM | 15 | 47% | 60% | |||
| Lazaridis et al. 2020 | ndGBM | 16 | 37% | ||||
| Song et al. 2020 | ndGBM | 10 | 80% | 30% | |||
| Bokstein et al. 2020 | ndGBM | 10 | 80% | ||||
| Zhu et al. 2020 (EF-19) | rGBM | 192 | 36% | ||||
| Shi et al. 2020 | ndGBM | 5887 | 40% | <1% | 8% | 11% | 11% |
| rGBM | 4345 | 31% | 7% | 10% | 9% |
Abbreviations: dAEs, dermatologic adverse events; rGBM, recurrent glioblastoma; ndGBM, newly diagnosed glioblastoma.